Ordering Recommendation

Consider ordering for individuals with paraneoplastic encephalomyelitis, chorea, cerebellar degeneration, optic neuritis, and peripheral neuropathy. May aid in diagnosis of occult or recurrent tumor.

Mnemonic
CV2.1 SCRN
Methodology

Semi-Quantitative Indirect Fluorescent Antibody

Performed

Thu

Reported

1-8 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Serum Separator Tube (SST) or Plain Red

Specimen Preparation

Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.25 mL)

Storage/Transport Temperature

Refrigerated

Unacceptable Conditions

Hemolyzed, contaminated, or severely lipemic specimens

Remarks
Stability

Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year

Reference Interval

Less than 1:10

Interpretive Data

CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.

Compliance Category

Laboratory Developed Test (LDT)

Note

If CV2.1 Antibody IgG Screen by IFA is positive, then CV2.1 Antibody IgG Titer by IFA will be added. Additional charges apply.

Hotline History
N/A
CPT Codes

86255; if reflexed, add 86256

Components
Component Test Code* Component Chart Name LOINC
2013959 CV2.1 Antibody IgG Screen by IFA
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
CV2.1 Screen by IFA with Reflex to Titer